In this study, we collected clinical and imaging data and final pathological findings from all 10 HER2-negative patients to evaluate the efficacy and safety of diagnostic ultrasound combined with contrast agent microbubbles and chemotherapy agents in patients with breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.